

Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases

S Katakura, T Nagahara, T Hara, S Kunitada, M Iwamoto

Exploratory Research Laboratories 2, Daiichi Pharmaceutical Co Ltd, 1-16-13, Kita-Kasai, Edogawa-ku, Tokyo 134, Japan

(Received 18 October 1994; accepted 21 December 1994)

Summary — Molecular modeling of a complex between factor Xa (FXa) and DX-9065a, a novel FXa inhibitor, has demonstrated a salt-bridge interaction of the amidinonaphthalene moiety of the inhibitor to the S1 site pocket of the enzyme and a crucial carboxyl group of the inhibitor for the FXa/thrombin selectivity. In the present study, we synthesized some DX-9065a derivatives and studied their interaction modes with FXa, trypsin and thrombin to evaluate the role of the acetimidoylpyrrolidine moiety. The docking study of the inhibitor in the FXa model provided a molecular model of the inhibitor–FXa complex showing a hydrophobic interaction of the pyrrolidine ring with an aryl binding site of FXa, and a hydrogen bond between the acetimidoyl group and the backbone carbonyl oxygen of Glu97. Comparison between the interaction mode of DX-9065a with FXa and those with trypsin and thrombin explained the inhibitory potencies of the enzymes.

molecular modeling / factor Xa / DX-9065a / thrombin / trypsin

Introduction

Factor Xa (FXa) is a trypsin-like serine protease involved in the cascade of blood coagulation. Although FXa is a promising target for anticoagulant agents [1], no synthetic inhibitor of FXa has been developed yet. In an earlier study, we reported a novel FXa inhibitor, (2*S*)-2-[4-[[[(3*S*)-acetimidoyl-3-pyrrolidinyl]oxy]phenyl]-3-(7-amidino-2-naphthyl)propanoic acid hydrochloride pentahydrate, DX-9065a (fig 1) [2]. This compound has a potent inhibitory activity for FXa and high selectivity for FXa over other serine proteases.

In a previous paper, we investigated the binding mode of DX-9065a by computer molecular modeling [3]. A docking study of DX-9065a into a three-dimensional model of FXa, based on the X-ray crystallographic data for trypsin [4], indicated that the amidinonaphthalene moiety of the inhibitor binds to the S1 site of FXa with a salt-bridge interaction. Furthermore, the Glu192 of thrombin corresponding to the Gln192 of FXa evokes an electrostatic repulsion of the carboxyl group of the inhibitor, which explains a mechanism of the FXa/thrombin selectivity of DX-9065a. However, DX-9065a has two basic terminals in the structure, suggesting that the acetimidoylpyrrolidine and the amidinonaphthalene moieties significantly participate in the potent inhibitory activity against FXa.

The acetimidoylpyrrolidine moiety also may contribute to the selectivity of DX-9065a for FXa from thrombin. The interaction of the moiety with a site of thrombin may fix the direction of the carboxyl group of DX-9065a, which leads to an increase in the electrostatic repulsion between the carboxyl group of the inhibitor and Glu192 of the enzyme. Thereby, DX-9065a cannot bind to thrombin. In addition, a loss of such an electrostatic repulsion between trypsin and DX-9065a suggests that the carboxyl group does not contribute to the selectivity for FXa from trypsin, and the acetimidoylpyrrolidine moiety should be involved in the selectivity.

In the present study, we determined a contribution of the acetimidoylpyrrolidine moiety of DX-9065a in




Fig 1. Structure of DX-9065a. Torsion angles rotated during a conformational search are shown with arrows.

the potency and selectivity for FXa by a molecular modeling technique. First, we synthesized a series of compounds **7a–d** in order to evaluate the interactions of the acetimidoylpyrrolidine moiety with FXa, thrombin and trypsin. Second, diverse low-energy conformers of DX-9065a were generated by the conformational search using a Metropolis Monte-Carlo method. Finally, on the basis of the SAR of the series of inhibitors, docking studies of these conformers into FXa, thrombin and trypsin were performed.


Chemistry

Compounds **6a–c** were prepared by the method described previously (scheme 1) [5]. Treatment of compounds **6b,c** with hydrochloride in ethanol and then with an ammonia/ethanol solution gave the amidine derivatives, which were hydrolyzed with hydrochloric acid to afford compounds **7b,c**. Acid hydrolysis of the amidine intermediate synthesized from **6a** gave the phenol derivative **7d**. Compound **7a**

was prepared along the following pathway with a modification: protection of the amidino group with *tert*-butoxy dicarbonate, alkali hydrolysis with sodium hydroxide and deprotection with trifluoroacetic acid.

Molecular modeling of serine proteases

The three-dimensional structure model of the heavy chain of human FXa was constructed on the basis of trypsin, a highly homologous serine protease, as described previously [3]. A recent X-ray crystallographic analysis of FXa revealed the geometric similarity of the α -carbons of FXa to those of thrombin, except for an insertion loop in thrombin, Tyr60A to Thr60I [6]. On the basis of this report, the coordinates from Asp170 to Ile176 of the FXa model, which were topologically different from those of thrombin, were replaced by the corresponding coordinates of thrombin, Leu170 to Ile176. Side chains of the resulting model were optimized manually to remove steric clashes, and then the FXa model was obtained by



Scheme 1. (a) R_1OH , diethyl azodicarboxylate, PPh_3 , THF; (b) R_1I , K_2CO_3 , DMF; (c) DBU, THF/EtOH; (d) Pd/C, H_2 , EtOH; (e) EtOH/HCl; EtOH/ NH_3 ; *tert*-butoxy dicarbonate, Et_3N , DMF; (f) 1 N NaOH; TFA; (g) EtOH/HCl; EtOH/ NH_3 ; 4 N HCl, Δ .

energy minimization of these residues in 500 steps without moving the other amino-acid residues.

The three-dimensional structure model of human α -thrombin was derived from the coordinates for the structure labeled 1DWE [7] in the Brookhaven Protein Data Bank [8]. Water molecules in the coordinates were removed and the hydrogens were added to the backbone and side chains based on the standard average bond angles and lengths.

The atomic coordinates of bovine trypsin registered as 1TPP [4] in the same data bank were employed as a template of the tertiary model of human trypsin (TRYI). After removal of water molecules and addition of hydrogens, the amino acids of bovine trypsin were replaced with those of human trypsin [9] by using the mutation option of the Quanta protein module. All side chains of the model were optimized by 500-step energy minimization. The numbering system of the enzymes was defined on the basis of topological equivalence with chymotrypsin.

Results and discussion





Structure-activity relationships

Anti-FXa and anti-thrombin activities of DX-9065a and its derivatives were measured as amidolytic activities for chromogenic substrates S-2222 and S-2338, respectively [2]. In a similar manner, anti-trypsin activity was measured using S-2222 (table I). Pyrrolidine derivative **2** and its acetimidoyl derivative **1** had almost same potency in FXa inhibitory activity [5]. Substitution of the methyl group of **7c** with a cyclopentyl group, forming compound **7a**, exhibited an eightfold increase in inhibitory potency. Replacement of the aminoethyl group of **7b** with the pyrrolidine ring gave compound **2** showing a 35-fold increase in potency. These results indicate importance of a terminal five-membered ring in the FXa inhibitors. The anti-FXa activity of pyrrolidine derivative **2** is 21 times as potent as that of cyclopentane derivative **7a**. Similarly, aminoethyl derivative **7b** is fivefold more potent than **7c**. These results indicate that the terminal amino group of the inhibitors contributes to the increase in potency. Thus, the pyrrolidine ring may be not only a constrained amino group but also a group contributing to a hydrophobic interaction with FXa.

The anti-trypsin activity of compounds **1**, **2**, and **7a-d**, unlike their anti-FXa activity, is almost the same. The hydrophobicity and basicity of the terminal substituents of the inhibitors are unlikely to be associated with the binding affinity for trypsin. Therefore, the FXa/trypsin selectivities of these inhibitors are primarily dependent on the anti-FXa activity.

The inhibitory activity of compounds **1**, **2**, and **7a-d** against thrombin was negligible.

Table I. Inhibitory activities of derivatives of DX-9065a on FXa, thrombin and trypsin.

Compound	R	IC ₅₀ (μ M)		
		FXa	Thrombin	Trypsin
1		0.16	>1000	10
2		0.20	>1000	5.4
7a		4.2	>1000	4.8
7b		7.3	>1000	10
7c	-CH ₃	35	>1000	7.5
7d	-H	26	>1000	16

Conformational search of DX-9065a

In order to sample diverse low-energy conformers efficiently, a Metropolis Monte-Carlo search procedure [10, 11] was applied to DX-9065a. The initial structure of DX-9065a was taken from its X-ray crystallographic structure [5]. To generate a conformer, six torsion angles ω_1 - ω_6 (see fig 1) were altered randomly within 45° at a pseudo-temperature of 5000K using Boltzmann jump search option of the Quanta program [12]. The generated conformer, whose dihedral root mean square difference from the previous conformer was over 43°, was accepted as a new conformer, which was subsequently optimized by 100-step minimization without changing the ring conformation of the pyrrolidine. This procedure was iterated 5000 times.

Conformers with the torsion angle ω_2 of $180 \pm 10^\circ$ were removed since their acetimidoylpyrrolidine moieties were incapable of binding to FXa. Elimination of conformers with energy levels more than 3 kcal/mol above the minimum gave 144 conformers. The conformational space shows that the acetimidoylpyrrolidine moiety is predominantly located in two

regions, as shown in figure 2. The resulting 144 conformers were docked into the FXa model to study the mode of interaction between the acetimidoylpyrrolidine moiety of DX-9065a and FXa.

Docking studies of DX-9065a

DX-9065a has two basic, amidinonaphthalene and acetimidoylpyrrolidine groups. The previous modeling study of the complex between FXa and DX-9065a demonstrated that the S1 pocket of FXa prefers the planar amidinonaphthalene group to the acetimidoylpyrrolidine group with a specially expanded structure [5]. Therefore, the amidinonaphthalene part of DX-9065a was adjusted to the S1 site to form a hydrogen-bonded ion pair of the amidino group with the carboxyl group of Asp189 of the enzyme without steric collisions. The docking study showed that 10 of the 144 conformers had a binding mode such that their




Fig 2. Superimposition of 144 conformers with an energy less than 3 kcal/mol above the minimum. The amidinonaphthalene, benzene and acetimidoylpyrrolidine moieties are displayed.

pyrrolidine rings interacted with a site of FXa corresponding to the 'aryl binding site' [13] of thrombin. The pyrrolidine ring was surrounded with Tyr99, Phe174 and Trp215 without any steric hindrance. This result is consistent with the model proposed by Padmanabhan *et al*, in which the dansyl group of dansyl-GluGlyArg, an FXa-inhibitor, interacts with the hydrophobic site of FXa [6], suggesting the hydrophobic interaction of the pyrrolidine ring with the aryl binding site. The pyrrolidine rings of the other conformers did not have such an interaction with FXa.

One of the 10 conformers was selected as a putative active conformer, since the acetimidoyl nitrogen was expected to form a hydrogen bond with the backbone carbonyl oxygen of Glu97. The hydrogen bond could explain the importance of the terminal basic group of the inhibitors **1**, **2** and **7b** in inhibitory potency. Energy-minimization of the complex between this conformer and the FXa model was performed in 500 steps without moving the α -carbons of FXa, to give a plausible model of DX-9065a bound to the enzyme. As shown in figure 3, the carbonyl oxygen of Glu97, which was located near the aryl binding site, appeared to donate a hydrogen bond to the acetimidoyl nitrogen. The distance between the two atoms was observed to be 2.8 Å, which was appropriate for a hydrogen bond. Alternatively, a salt-bridge interaction may be considered as an interaction between the terminal basic center of the inhibitor and the acidic side chain of Glu97. However, the hydrogen bond seemed preferable to the salt-bridge interaction since the orientation of the side chain of Glu97 was unfavorable for the tight interaction with the acetimidoyl group.

In addition, there was no hydrophobic site of FXa interacting with the benzene ring attached to the phenoxypyrrolidine moiety of all the 144 conformers. The ring might be a spacer to fix the pyrrolidine ring on the favorable location.

Trypsin also has a site, which consists of two hydrophobic Leu99 and Trp215 and a hydrophilic Lys175, corresponding to the aryl binding site of FXa. A docking study of DX-9065a in the trypsin model showed that the inhibitor could bind to the enzyme in a similar manner to FXa (fig 4). However, the hydrophobic binding of the acetimidoylpyrrolidine moiety with the site of trypsin may not be very strong as the site is less hydrophobic than that of FXa. This could account for the almost identical antitrypsin activities of **7a** and **7c**. In addition, an electrostatic repulsion between the pyrrolidine nitrogen and the basic side chain of Lys175 could weaken a hydrogen bond between the pyrrolidine nitrogen and the carbonyl oxygen of Glu97, explaining the almost identical antitrypsin activity of the compounds with or without the terminal basic nitrogen. Thus, comparison between the binding modes of DX-9065a with trypsin and FXa




Fig 3. Model structure of the complex between FXa (thin lines) and DX-9065a (thick lines).




Fig 4. Model structure of the complex between trypsin (thin lines) and DX-9065a (thick lines).

can give an explanation of the FXa/trypsin selectivity, which is ascribed to the acetimidoyl pyrrolidine moiety.

In the previous paper, we proposed the molecular mechanism of the FXa/thrombin selectivity of DX-9065a. An electrostatic repulsion between the carboxyl group of DX-9065a and that of Glu192 of thrombin causes the unfavorable enzyme-inhibitor contact and thereby extinguishes the inhibitory activity against thrombin [3]. Both thrombin and FXa have the aryl binding site which was formed with

Leu99, Ile174 and Trp215. A docking study of DX-9065a indicated that the site accommodated the pyrrolidine ring without steric clashes. In addition, thrombin also had Glu97 which seemed capable of forming a hydrogen bond with the amino terminal of DX-9065a. The interaction between the acetimidoylpyrrolidine moiety and the enzyme would fix the orientation of the carboxyl group of DX-9065a, which resulted in the electrostatic repulsion of the carboxyl group to Glu192 of thrombin (fig 5). However, compounds **7c** and **7d** without the acetimidoylpyrro-

lidine group have little inhibitory activity against thrombin. This result indicates that the carboxyl group of DX-9065a is solely related to the electrostatic repulsion leading to the FXa/thrombin selectivity.

In this paper, the conformational search was performed by the Metropolis Monte-Carlo method to sample various low-energy conformers efficiently. This method generated a plausible low-energy conformer of DX-9065a whose pyrrolidine and acetimidoyl moieties interacted with the aryl binding site and the Glu97 of FXa, respectively. This conformer could not be found by the previous systematic conformational analysis of DX-9065a [3]. Thus, the Metropolis Monte-Carlo method can efficiently provide plausible low-energy conformers when compounds have many rotatable bonds, as DX-9065a does.

In this procedure, the 144 conformers with low potential energy were selected by a criterion of 3 kcal/mol above the minimum. Alternatively, a criterion of 10 kcal/mol above the minimum offered the 2197 conformers. Ninety percent of the acetimidoyl-pyrrolidine group of these conformers had the same conformational space as those of the 144 conformers. The remaining were found to clash with FXa or had no hydrophobic interaction with FXa in the docking study (data not shown). Thus, the 144 conformers were sufficient for the evaluation of the binding mode of the acetimidoylpyrrolidine moiety with FXa.

The calculated energy of a drug–receptor interaction based on steric and electrostatic interactions may indicate favorable binding sites of the drug to receptors and/or enzymes [14]. However, a drug–

receptor interaction could not be assessed exactly by such a calculation because of the neglect of the entropic contribution to ΔG , which is predominant in some drugs [15]. Since DX-9065a has a flexible structure and possesses some hydrophobic interactions with FXa, the enzyme–inhibitor interaction may be incorrectly estimated by the energy calculations. Therefore, compounds **7a–d** were synthesized to evaluate such an entropic interaction. A combination of their SAR and the results of computer graphic techniques helped in the prediction of the putative binding sites. These results will not only improve the understanding of the enzyme–inhibitor interactions but also contribute to the research into new drugs.

Experimental protocols

Chemistry

Melting points were determined on a Büchi 520 apparatus in glass capillary tubes and are uncorrected. Column chromatography was performed on Merck silica gel 60 (70–230 mesh ASTM) and on Diaion HP-20 (highly porous polymer type synthetic adsorbent; Mitsubishi Chemical Industries). Thin-layer chromatography (TLC) was performed on Merck TLC aluminum sheets precoated with silica gel 60 F₂₅₄ and detected by UV quenching at 254 nm or by spraying with phosphomolybdic acid or ninhydrin. All analytical samples were found to be homogeneous on TLC. ¹H-NMR spectra were recorded on a Jeol JNM-EX400 spectrometer, and chemical shifts are given in ppm (δ) from tetramethylsilane, which was used as the internal standard. Mass spectra were performed using a Jeol JMS-AX505W (EI) or a Jeol JMS-HX110 (FD, FAB) spectrometer. Analyses indicated by the symbols of the elements or functions were within $\pm 0.4\%$ of theoretical values.




Fig 5. Model structure of the complex between thrombin (thin lines) and DX-9065a (thick lines).

Ethyl 2-[4-[(cyclopentyl)oxy]phenyl]-2-oxoacetate 4a

To a stirred solution of ethyl 2-(4-hydroxyphenyl)-2-oxoacetate (3.88 g, 20 mmol), cyclopentanol (1.72 g, 20 mmol) and triphenylphosphine (5.50 g, 21 mmol) in dry THF (30 ml) was added diethyl azodicarboxylate (3.65 g, 21 mmol) at room temperature. The reaction mixture was stirred for 18 h and concentrated. The resulting residue was purified by silica-gel chromatography using toluene to afford an oil (4.50 g, 85.8%). ¹H-NMR (CDCl₃) δ: 1.41 (3H, t, *J* = 7.3 Hz), 1.55–2.00 (8H, m), 4.42 (2H, q, *J* = 7.3 Hz), 4.80–4.90 (br s, 1H), 6.90 (2H, d, *J* = 8.8 Hz), 7.96 (2H, d, *J* = 8.8 Hz). HRMS (M⁺) calcd for C₁₅H₁₈O₄: 262.1205; found: 262.1218.

Ethyl 2-[4-[[2-(tert-butoxycarbonylamino)ethyl]oxy]phenyl]-2-oxoacetate 4b

Compound **4b** was prepared from ethyl 2-(4-hydroxyphenyl)-2-oxoacetate and 2-(tert-butoxycarbonylamino)ethanol according to the procedure for preparation of **4a**. Purification was carried out using silica-gel chromatography (toluene/acetone = 93:7) to give an oil (yield 38.5%). ¹H-NMR (CDCl₃) δ: 1.42 (3H, t, *J* = 7.3 Hz), 1.45 (9H, s), 3.50–3.63 (2H, m), 4.05–4.15 (2H, m), 4.43 (2H, q, *J* = 7.3 Hz), 4.95–5.05 (1H, br), 6.96 (2H, d, *J* = 8.8 Hz), 8.00 (2H, d, *J* = 8.8 Hz). MS (FD) *m/z*: 337 M⁺.

Ethyl 2-(4-methoxyphenyl)-2-oxoacetate 4c

To a stirred solution of ethyl 2-(4-hydroxyphenyl)-2-oxoacetate (3.88 g, 20 mmol) and methyl iodide (2 ml) in dry DMF (50 ml) was added anhydrous K₂CO₃ (2.90 g, 21 mmol). The mixture was heated at 80°C for 30 min, cooled to room temperature, and neutralized with concentrated HCl. The resulting mixture was poured into water and extracted with toluene. The organic layer was dried and concentrated to give an oil (3.67 g, 88.2%). ¹H-NMR (CDCl₃) δ: 1.40 (3H, t, *J* = 7.0 Hz), 3.87 (3H, s), 4.42 (2H, q, *J* = 7.0 Hz), 6.95 (2H, d, *J* = 9.0 Hz), 7.98 (2H, d, *J* = 9.0 Hz). HRMS (M⁺) calcd for C₁₁H₁₂O₄: 208.0736; found: 208.0719.

[[7-(Cyano-2-naphthyl)methyl]triphenylphosphonium bromide 5
This was prepared according to the described previously procedure [1].**Ethyl 3-(7-cyano-2-naphthyl)-2-[4-[(cyclopentyl)oxy]phenyl]propanoate 6a**

To a stirred solution of **4a** (1.30 g, 5.0 mmol) and **5** (2.60 g, 5.0 mmol) in dry THF (20 ml)/EtOH (20 ml) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (835 mg, 5.5 mmol) at room temperature. The reaction mixture was stirred for 18 h at room temperature and concentrated. The residue was purified by silica-gel chromatography using toluene/AcOEt (9:1) to give a mixture of *E*- and *Z*-ethyl 2-(7-cyano-2-naphthyl)-3-[4-[(cyclopentyl)oxy]phenyl]acrylate as an oil (1.9 g). The mixture of the above *E*- and *Z*-olefins (1.9 g) in dry THF (80 ml)/EtOH (50 ml) was hydrogenated over 5% Pd/C (900 mg) at atmospheric pressure for 5 h. The resulting mixture was filtered and concentrated. The residue was purified by silica-gel column chromatography using toluene to provide a colorless solid (1.60 g, 78.1%), mp 85–86°C. ¹H-NMR (CDCl₃) δ: 1.10 (3H, t, *J* = 7.3 Hz), 1.55–2.00 (8H, m), 3.17 (1H, dd, *J* = 13.7 and 6.8 Hz), 3.54 (1H, dd, *J* = 13.7 and 8.3 Hz), 3.80–3.90 (1H, m), 3.95–4.15 (2H, m), 4.65–5.75 (1H, m), 6.80 (2H, d, *J* = 8.8 Hz), 7.20 (2H, d, *J* = 8.8 Hz), 7.42 (1H, d, *J* = 8.3 Hz), 7.53 (1H, d, *J* = 8.3 Hz), 7.60 (1H, s), 7.76 (1H, d, *J* = 8.3 Hz), 7.84 (1H, d, *J* = 8.3 Hz), 8.11 (1H, s). HRMS (M⁺) calcd for C₂₇H₂₇NO₃: 413.1991; found: 413.2014. Anal C₂₇H₂₇NO₃ (C, H, N).

Ethyl 2-[4-[[2-(tert-butoxycarbonylamino)ethyl]oxy]phenyl]-3-(7-cyano-2-naphthyl)propanoate 6b

Prepared from **4b** according to the procedure for preparation of **4a** as a colorless solid (yield 25.6%), mp 94–95°C. ¹H-NMR (CDCl₃) δ: 1.10 (3H, t, *J* = 7.3 Hz), 1.44 (9H, s), 3.18 (1H, dd, *J* = 13.7 and 6.8 Hz), 3.45–3.60 (3H, m), 3.85–3.93 (1H, m), 3.95–4.15 (4H, m), 4.97–5.10 (1H, br s), 6.82 (2H, d, *J* = 8.3 Hz), 7.23 (2H, d, *J* = 8.3 Hz), 7.40 (1H, d, *J* = 8.3 Hz), 7.51 (1H, d, *J* = 8.3 Hz), 7.60 (1H, s), 7.74 (1H, d, *J* = 8.3 Hz), 7.82 (1H, d, *J* = 8.3 Hz), 8.08 (1H, s). Anal C₂₉H₃₂N₂O₅ (C, H, N).

Ethyl 3-(7-cyano-2-naphthyl)-2-(4-methoxyphenyl)propanoate 6c

Prepared from **4c** according to the procedure for preparation of **6a** as a colorless solid (yield 57.9%), mp 91–92°C. ¹H-NMR (CDCl₃) δ: 1.11 (3H, t, *J* = 7.3 Hz), 3.18 (1H, dd, *J* = 13.7 and 6.8 Hz), 3.55 (1H, dd, *J* = 13.7 and 8.3 Hz), 3.79 (3H, s), 3.80–3.90 (1H, m), 4.00–4.15 (2H, m), 6.84 (2H, d, *J* = 8.8 Hz), 7.23 (2H, d, *J* = 8.8 Hz), 7.42 (1H, d, *J* = 8.3 Hz), 7.54 (1H, d, *J* = 8.3 Hz), 7.61 (1H, s), 7.77 (1H, d, *J* = 8.3 Hz), 7.85 (1H, d, *J* = 8.3 Hz), 8.12 (1H, s). Anal C₂₃H₂₁NO₃ (C, H, N).

3-(7-Amidino-2-naphthyl)-2-[4-[(cyclopentyl)oxy]phenyl]propanoic acid hydrochloride hemihydrate 7a

A solution of **6a** (920 mg, 2.2 mmol) in dry CH₂Cl₂ (10 ml)/EtOH (30 ml) was saturated with HCl gas with ice cooling, and left to stand for 18 h at room temperature. After distilling off the solvents and HCl, the resulting residue was dissolved in EtOH (40 ml), saturated with ammonia gas with ice cooling and left to stand for 18 h at room temperature. The mixture was concentrated, and the resulting residue was dissolved in dry DMF (20 ml). To the solution were added *tert*-butoxy dicarbonate (483 mg, 2.2 mmol) and triethylamine (446 mg, 4.4 mmol). The mixture was stirred for 3 h at room temperature, acidified with concentrated HCl and concentrated. The resulting residue was extracted with AcOEt. The organic layer was washed, dried and concentrated. The residue was purified by silica-gel column chromatography using acetone/CH₂Cl₂ (1:9) to afford ethyl 3-[7-(*N*-*tert*-butoxycarbonylamidino)-2-naphthyl]-2-[4-[(cyclopentyl)oxy]phenyl]propanoate as an oil (530 mg). To a stirred solution of the oil (530 mg, 2.2 mmol) in THF (5 ml)/EtOH (5 ml)/H₂O (5 ml) was added 1 N NaOH (1.0 ml, 1.0 mmol). The reaction mixture was stirred for 20 h at room temperature. The mixture was acidified with 10% citric acid and extracted with AcOEt/toluene (1:1). The organic layer was dried and concentrated. The resulting residue was dissolved in trifluoroacetic acid (5 ml) and stirred for 1 h at room temperature. The solvent was removed, and the residue was purified by HP-20 column chromatography (acetonitrile/H₂O (7:93)). After addition of small amount of concentrated HCl to desired fractions, the solvent was removed to give a colorless solid (150 mg, 15.3%). ¹H-NMR (DMSO-*d*₆) δ: 1.45–2.00 (8H, m), 3.14 (1H, dd, *J* = 14.0 and 6.8 Hz), 3.46 (1H, dd, *J* = 14.0 and 8.8 Hz), 3.96 (1H, t, *J* = 7.3 Hz), 4.75 (1H, br), 6.82 (2H, d, *J* = 8.5 Hz), 7.25 (2H, d, *J* = 8.5 Hz), 7.60 (1H, d, *J* = 8.3 Hz), 7.78 (1H, d, *J* = 8.8 Hz), 7.84 (1H, s), 7.94 (1H, d, *J* = 8.3 Hz), 8.07 (1H, d, *J* = 8.8 Hz), 8.39 (1H, s), 9.29 (2H, br), 9.51 (2H, br), 12.34 (1H, br). MS (FAB) *m/z*: 403 (M + H)⁺. Anal C₂₅H₂₆N₂O₃·HCl·1/2H₂O (C, H, N, Cl).

3-(7-Amidino-2-naphthyl)-2-[4-[(2-aminoethyl)oxy]phenyl]propanoic acid dihydrochloride hydrate 7b

A solution of **6b** (600 mg, 1.2 mmol) in dry CH₂Cl₂ (10 ml)/EtOH (40 ml) was saturated with HCl gas under ice cooling and left to stand for 18 h at room temperature. After distilling

off the solvents and HCl, the resulting residue was dissolved in EtOH (50 ml). The solution was saturated with NH₃ gas with ice cooling and left to stand for 18 h at room temperature. The mixture was concentrated, and the resulting residue was dissolved in 4 N HCl and heated at reflux for 1 h. After cooling to room temperature, the precipitate was collected by filtration to give a colorless solid (200 mg, 34.5%). ¹H-NMR (DMSO-*d*₆) δ: 3.10–3.20 (3H, m), 3.48 (1H, dd, *J* = 14.2 and 8.3 Hz), 3.97–4.06 (1H, m), 4.12–4.20 (2H, m), 6.92 (2H, d, *J* = 8.8 Hz), 7.30 (2H, d, *J* = 8.8 Hz), 7.56–7.64 (1H, m), 7.77–7.86 (2H, m), 7.94 (1H, d, *J* = 8.8 Hz), 8.07 (1H, d, *J* = 8.8 Hz), 8.25–8.45 (3H, br), 8.43 (1H, s), 9.41 (2H, br), 9.61 (2H, br). MS (FAB) *m/z*: 378 (M + H)⁺. Anal C₂₂H₂₃N₃O₃·2HCl·H₂O (C, H, N); Cl: calcd 15.14; found, 16.11.

3-(7-Amidino-2-naphthyl)-2-(4-methoxyphenyl)propanoic acid hydrochloride hemihydrate 7c

Compound 7c was prepared from 6c according to the procedure for the preparation of 7b. Purification was carried out using HP-20 column chromatography (acetonitrile/H₂O (7:93)) to give a colorless amorphous solid (yield 47.5%), mp 195°C (dec). ¹H-NMR (DMSO-*d*₆) δ: 3.15 (1H, dd, *J* = 13.7 and 6.8 Hz), 3.47 (1H, dd, *J* = 14.0 and 8.5 Hz), 3.71 (3H, s), 3.90–4.00 (1H, m), 6.86 (2H, d, *J* = 8.8 Hz), 7.27 (2H, d, *J* = 8.8 Hz), 7.60 (1H, d, *J* = 8.3 Hz), 7.75 (1H, d, *J* = 8.8 Hz), 7.84 (1H, s), 7.94 (1H, d, *J* = 8.8 Hz), 8.07 (1H, d, *J* = 8.8 Hz), 8.36 (1H, s), 9.20 (2H, br), 9.46 (2H, br), 12.34 (1H, br). MS (FAB) *m/z*: 349 (M + H)⁺. Anal C₂₁H₂₀N₂O₃·HCl·0.5H₂O (C, H, N, Cl).

3-(7-Amidino-2-naphthyl)-2-(4-hydroxyphenyl)propanoic acid hydrochloride 7d

Compound 7d was prepared from 6d according to the procedure for the preparation of 7b as a colorless solid (yield 62.4%), mp 225°C (dec). ¹H-NMR (DMSO-*d*₆) δ: 3.13 (1H, dd, *J* = 14.0 and 6.8 Hz), 3.44 (1H, dd, *J* = 14.0 and 8.5 Hz), 3.89 (1H, t, *J* = 7.8 Hz), 6.69 (2H, d, *J* = 8.8 Hz), 7.14 (2H, d, *J* = 8.8 Hz), 7.59 (1H, d, *J* = 8.3 Hz), 7.76 (1H, d, *J* = 8.3 Hz), 7.82 (1H, s), 7.94 (1H, d, *J* = 8.3 Hz), 8.06 (1H, d, *J* = 8.3 Hz), 8.37 (1H, s), 9.21 (2H, br), 9.36 (1H, s), 9.46 (2H, br), 12.27 (1H, br). MS (FAB) *m/z*: 335 (M + H)⁺. Anal C₂₀H₁₈N₂O₃·HCl (C, H, N, Cl).

Energy calculations

All procedures were performed on an Iris 320 GTX computer from Silicon Graphics Incorporation. Energy calculations were carried out using the force field of version 2.2 of the Charm/m program [16]. The cut-off distance and the distance-dependent dielectric constant ε were set to 8.0 Å and 4 *r*_{ij}, respectively.

Energy minimizations were executed by the Charm/m minimization option of the Quanta program (method: adopted basis Newton-Raphson; energy gradient tolerance: 0.001 kcal/molÅ²).

Pharmacology. Assay of anti-trypsin activity

Anti-trypsin activities were measured by using chromogenic substrate S-2222 (Kabi Vitrum) and human trypsin (Athens Research and Technology, Inc). DMSO (50 μl) or a DMSO solution of the inhibitor and 1 mM S-2222 (100 μl) were mixed with 0.1 M Tris-0.2 M NaCl buffer at pH 8.4 (300 μl). The reaction was started with the addition of 1 μg/ml human trypsin solution (50 μl), and the mixture was incubated for 10 min at 37°C. The reaction was terminated with the addition of 60% AcOH (100 μl), and the optical densities (OD) were measured (405 nm): anti-trypsin activity (inhibition %) = 1 – (OD of the inhibitor/ OD of saline control) × 100. The IC₅₀ value was obtained by plotting the inhibitor concentration against the anti-trypsin activity (inhibition %) on statistical probability paper.

References

- 1 Sixma JJ, de Groot PG (1993) *Thromb Res* 68, 507–512
- 2 Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M (1994) *Thromb Haemostasis* 71, 314–319
- 3 Katakura S, Nagahara T, Hara T, Iwamoto M (1993) *Biochem Biophys Res Commun* 197, 965–972
- 4 Marquart M, Walter J, Deisenhofer J, Bode W, Huber R (1983) *Acta Crystallogr Sect B* 39, 480–490
- 5 Nagahara T, Yokoyama Y, Inamura K, Katakura S, Iwamoto M (1994) *J Med Chem* 37, 1200–1207
- 6 Padmanabhan K, Padmanabhan KP, Tulinsky A *et al* (1993) *J Mol Biol* 232, 947–966
- 7 Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J (1989) *EMBO J* 8, 3467–3479
- 8 Protein Data Bank, Brookhaven National Laboratory, Upton, NY, USA
- 9 Emi M, Nakamura Y, Ogawa M *et al* (1986) *Gene* 41, 305–310
- 10 Metropolis NA, Rosenbluth AW, Rosenbluth MN, Teller AH, Teller EJ (1953) *J Chem Phys* 21, 1987
- 11 Li Z, Sheraga HA (1987) *Proc Natl Acad Sci USA* 84, 6611–6615
- 12 Molecular Simulation Inc, New England Executive Park, Burlington, MA, USA
- 13 Bode W, Turk D, Stürzebecher J (1990) *Eur J Biochem* 193, 175–182
- 14 Leach AR, Kuntz ID (1992) *J Comp Chem* 13, 730–748
- 15 Hitzemann R (1988) *Trends in Pharmacol Sci* 9, 408–411
- 16 Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M (1983) *J Comput Chem* 4, 187–217